The efficacy and safety of the combination of leflunomide (Arava) and biological agents in treatment of rheumatoid arthritis
Novak, S.
Reumatizam 55(2): 68-69
2008
ISSN/ISBN: 0374-1338 PMID: 19024279 Document Number: 621303
The efficacy and safety of the combination of leflunomide (Arava) with biological agents in treatment of rheumatoid arthritisiare presented.
Document emailed within 1 workday
Related Documents
Godinho, F.; Godfrin, B.; El Mahou, S.; Navaux, F.; Zabraniecki, L.; Cantagrel, A. 2004: Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis Clinical and Experimental Rheumatology 22(3): 328-330Carreira Delgado, P.E.; Gómez-Reino Carnota, J.J.; Morillas López, L.; Ibero Díaz, I.; Mateo Bernardo, I. 1986: Effectiveness and safety of immunosuppressive agents in the treatment of rheumatoid arthritis Medicina Clinica 86(14): 575-578
Bathon, J.M.; Fleischmann, R.M.; Van der Heijde, Désirée.; Tesser, J.R.; Peloso, P.M.; Chon, Y.; White, B. 2006: Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis Journal of Rheumatology 33(2): 234-243
Osiri, M.; Shea, B.; Robinson, V.; Suarez-Almazor, M.; Strand, V.; Tugwell, P.; Wells, G. 2003: Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis Journal of Rheumatology 30(6): 1182-1190
Grzywa, M.; Kadziela, M.łg. 2013: The conversion of hypothyroidism into hyperthyroidism during leflunomide with povidone iodine treatment of rheumatoid arthritis Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 34(204): 348-350
Kondo, H.; Abe, T.; Hashimoto, H.; Uchida, S.; Irimajiri, S.; Hara, M.; Sugawara, S. 2004: Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study Journal of Rheumatology 31(2): 243-251
Ilić, T.; Milić, B.; Ćelić, D.; Vučković, B.; Mitić, I. 2013: Etanercept therapy in rheumatoid arthritis: efficacy and safety Srpski Arhiv Za Celokupno Lekarstvo 141(7-8): 495-502
Lemmel, E.M.; Bolten, W.; Burgos-Vargas, R.; Platt, P.; Nissilä, M.; Sahlberg, D.; Björneboe, O.; Baumgartner, H.; Valat, J.P.; Franchimont, P.; Bluhmki, E.; Hanft, G.; Distel, M. 1997: Efficacy and safety of meloxicam in patients with rheumatoid arthritis Journal of Rheumatology 24(2): 282-290
Furst, D.E.; Schiff, M.H.; Fleischmann, R.M.; Strand, V.; Birbara, C.A.; Compagnone, D.; Fischkoff, S.A.; Chartash, E.K. 2003: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) Journal of Rheumatology 30(12): 2563-2571
Biasi, D.; Caramaschi, P.; Carletto, A.; Pacor, M.L.; Bambara, L.M. 1997: Safety of combination therapy with hydroxychloroquine, gold sodium thiomalate and methotrexate in early rheumatoid arthritis Revue du Rhumatisme 64(7-9): 521-522
Drosos, A.A.; Voulgari, P.V. 2001: Long-term efficacy and toxicity of a combination therapy in rheumatoid arthritis patients Clinical and Experimental Rheumatology 19(1): 111
Shinozawa, T.; Kameda, H.; Hama, N.; Yoshida, T.; Ohosone, Y.; Ichikawa, Y. 1998: The efficacy of combination therapy with prednisolone (PSL) and methotrexate (MTX) on radiographic progression in patients with rheumatoid arthritis (RA) Ryumachi 38(1): 14-22
Berdnik-Gortan, K.; Bjelinski, D. 1999: Effect of combination therapy and nonsteroidal antirheumatic agents on acute phase reactants in patients with rheumatoid arthritis Reumatizam 46(1): 12-16
Fleishmann, R.M. 2002: Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents Clinical and Experimental Rheumatology 20(5 Suppl 27: S35-S41
Alekseeva, L.I. 2010: Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program) Terapevticheskii Arkhiv 82(8): 57-62
De Filippis, L.; Caliri, A.; Anghelone, S.; Scibilia, G.; Lo Gullo, R.; Bagnato, G. 2006: Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis Panminerva Medica 48(2): 129-135
Valesini, G.; Montecucco, C.; Cutolo, M. 2006: Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy Clinical and Experimental Rheumatology 24(4): 413-423
Criswell, L.A.; Henke, C.J. 1995: What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis? Journal of Rheumatology 22(5): 829-835
Pomirleanu, C.; Ancuţa, C.; Macovei, L.; Chirieac, R. 2012: Prospective study of the efficiency and safety of adalimumab in treatment of active established rheumatoid arthritis Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 116(2): 395-400
Michaels, R.M.; Reading, J.C.; Beezhold, D.H.; Ward, J.R. 1996: Serum phospholipase A2 activity in patients with rheumatoid arthritis before and after treatment with methotrexate, auranofin, or combination of the two Journal of Rheumatology 23(2): 226-229